ADAM10 and rheumatoid arthritis: IL-6R was shown to be important in cancer (Deng et al., 2019; He et al., 2019; Weng et al., 2019; Yousefi et al., 2019) and RA (Ahmed et al., 2017) suggesting that ADAM10-mediated cleavage of IL-6R can be targeted for drug discovery for both indications.